Navigation Links
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:10/7/2008

- Data Presented Today at ACG Annual Scientific Meeting -

ORLANDO, Fla., Oct. 7 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of results from a Phase 2b study assessing linaclotide's safety and efficacy in 420 patients with irritable bowel syndrome with constipation (IBS-C). Analysis of the data indicates that once- daily oral dosing of linaclotide, across a range of doses, significantly reduced abdominal pain and significantly improved constipation symptoms in patients with IBS-C throughout the 12-week study period. Further, the safety and tolerability profile support advancing this novel compound into Phase 3 clinical trials. The study results were presented today in a plenary session at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting in Orlando, Fla.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

"Patients with IBS-C are in need of effective and well tolerated therapies. The results of this study showing improvement in abdominal pain and constipation are encouraging," said Douglas Drossman, M.D., Professor of Medicine and Psychiatry at UNC School of Medicine, Division of Gastroenterology and Hepatology and Co-Director of the UNC Center for Functional GI & Motility Disorders, University of North Carolina at Chapel Hill, N.C.

Study Results

420 patients were randomized into the study and 337 completed the 12-week treatment period. At all linaclotide dose levels, the change from baseline vs. placebo for complete spontaneous bowel movement (CSBM) frequency-the st
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
2. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
3. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
4. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
5. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
6. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will present at the 16th Annual B. Riley ... 13, 2015. The conference will be held May 12-14, 2015 ... Heska management will be available during the day on ...
(Date:5/1/2015)... , May 1, 2015 Braeburn ... its current therapeutic focus beyond addiction and ... psychiatric disorders. Braeburn has acquired an implantable, ... antipsychotic risperidone for treatment of schizophrenia from ... acquires global rights to other potential applications ...
(Date:5/1/2015)...  Boston Scientific Corporation (NYSE: BSX ) is ... long-term growth strategies at a meeting with the investment ... . President and Chief Executive Officer Mike Mahoney ... to bring forward meaningful innovation to transform patient care, ... value. "We are focused on addressing ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... LYNDHURST, N.J., Aug. 30 A molecular,diagnostic ... 85,developmental disorders affecting children now is commercially ... testing and,reimbursement by leading health plans across ... ), the nation,s leading provider of diagnostic,testing, ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... commercializing proprietary product candidates principally,for use in ... completed patient,enrollment in a pivotal Phase III ... intravenous acetaminophen (IV,acetaminophen), for the treatment of ...
Cached Medicine Technology:Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 2Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 3Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 4Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 2Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 3Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 4Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 5
(Date:5/2/2015)... Peachtree Audio ” was featured on NewsWatch as part ... and coolest technology products available to consumers. Scott Steinberg, ... the review and shared with viewers how this is ... important part of people’s lives – and as such, ... Peachtree Audio does just that with high-end audio equipment ...
(Date:5/2/2015)... Kare Visits LLC. launched in Chicago in response ... Kare Visits offers relief for caregivers by visiting loved ones ... According to the Caregiver Action Network, eight in ten caregivers ... a week caring for an elderly or disabled loved one. ... nurse, a caregiver is now empowered to schedule an on ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
(Date:5/1/2015)... IDLife LLC, a health and wellness company headquartered ... of its newest partner and fitness celebrity, Jen Widerstrom. ... up in gymnastics and competitive diving, but truly found ... trainer and helping others achieve their fitness aspirations. Jen ... highlighting her stunning physique and unique training techniques. ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood company in ... wood products at the 27th annual International Contemporary Furniture ... this May. Their newest offerings, Vat 35, Mushroom Boards, ... color to North America's platform for global design. ... in the design world and we're excited to share ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3
... of students nationwide prepare to leave high school, a UC ... the medical journal Pediatrics shows a clear link ... as kindergarten and lower high school test scores. , ... they start school had the strongest negative effect on how ...
... now have a new and simple way to diagnose ... to David Kaelber, M.D., Ph.D., M.P.H., MetroHealth System pediatrician, ... Reserve University School of Medicine researcher and faculty member. ... of cases of prehypertension in children and adolescents go ...
... prior research on the cholesterol-lowering drugs , , MONDAY, May 25 ... reduces the risk of a second stroke, new research shows. ... strokes found a 35 percent lower incidence of second strokes ... took statins compared to those who didn,t, according to a ...
... for bulk vaccine valued at $190 million -SWIFTWATER, Pa. and ... of the sanofi-aventis Group (EURONEXT: SAN and NYSE: ... what is expected to be a series of orders from ... commence production of a vaccine to help protect against the ...
... The general health of toddlers in,the SAR has room ... Hong,Kong Institute of Asia-Pacific Studies at the Chinese ... today to announce the results, a researcher from,CUHK as ... registered dietician,all agreed that, based on the survey, many ...
... to manufacturers by month,s end, CDC says , , SUNDAY, ... progress towards a viable H1N1 swine flu vaccine this ... Control and Prevention saying they had two promising candidate ... CDC received, from one institution, a candidate vaccine virus," ...
Cached Medicine News:Health News:Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find 2Health News:Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find 3Health News:Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find 4Health News:Pediatrician creates easier way to identify kids' high BP 2Health News:Statins Can Help Prevent Second Stroke 2Health News:Statins Can Help Prevent Second Stroke 3Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 2Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 3Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 4Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 5Health News:CUHK Releases Results of 'Survey on Toddler Health in Hong Kong' 2Health News:CUHK Releases Results of 'Survey on Toddler Health in Hong Kong' 3Health News:CUHK Releases Results of 'Survey on Toddler Health in Hong Kong' 4Health News:U.S. Closer to Viable Swine Flu Shot 2Health News:U.S. Closer to Viable Swine Flu Shot 3Health News:U.S. Closer to Viable Swine Flu Shot 4Health News:U.S. Closer to Viable Swine Flu Shot 5Health News:U.S. Closer to Viable Swine Flu Shot 6Health News:U.S. Closer to Viable Swine Flu Shot 7Health News:U.S. Closer to Viable Swine Flu Shot 8Health News:U.S. Closer to Viable Swine Flu Shot 9Health News:U.S. Closer to Viable Swine Flu Shot 10Health News:U.S. Closer to Viable Swine Flu Shot 11Health News:U.S. Closer to Viable Swine Flu Shot 12Health News:U.S. Closer to Viable Swine Flu Shot 13
Round serrated handle, dull finish....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: